GT Biopharma (GTBP) Competitors $2.37 +0.08 (+3.49%) Closing price 04/15/2025 03:48 PM EasternExtended Trading$2.36 -0.01 (-0.42%) As of 04/15/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. TENX, PASG, CARA, LIAN, CGTX, FNCH, OVID, LGVN, PULM, and RVPHShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Tenax Therapeutics (TENX), Passage Bio (PASG), Cara Therapeutics (CARA), LianBio (LIAN), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Ovid Therapeutics (OVID), Longeveron (LGVN), Pulmatrix (PULM), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Tenax Therapeutics Passage Bio Cara Therapeutics LianBio Cognition Therapeutics Finch Therapeutics Group Ovid Therapeutics Longeveron Pulmatrix Reviva Pharmaceuticals Tenax Therapeutics (NASDAQ:TENX) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Does the media favor TENX or GTBP? In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 2 articles in the media. GT Biopharma's average media sentiment score of 1.46 beat Tenax Therapeutics' score of 0.93 indicating that GT Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Tenax Therapeutics Positive GT Biopharma Positive Do insiders and institutionals have more ownership in TENX or GTBP? 1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by insiders. Comparatively, 10.9% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, TENX or GTBP? Tenax Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$7.71M-$5.32-1.04GT BiopharmaN/AN/A-$7.60M-$7.00-0.34 Which has more volatility and risk, TENX or GTBP? Tenax Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Does the MarketBeat Community favor TENX or GTBP? Tenax Therapeutics received 28 more outperform votes than GT Biopharma when rated by MarketBeat users. However, 63.24% of users gave GT Biopharma an outperform vote while only 54.92% of users gave Tenax Therapeutics an outperform vote. CompanyUnderperformOutperformTenax TherapeuticsOutperform Votes14554.92% Underperform Votes11945.08% GT BiopharmaOutperform Votes11763.24% Underperform Votes6836.76% Is TENX or GTBP more profitable? Tenax Therapeutics' return on equity of -46.00% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -46.00% -42.65% GT Biopharma N/A -257.47%-131.09% Do analysts recommend TENX or GTBP? Tenax Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 224.32%. GT Biopharma has a consensus price target of $11.00, suggesting a potential upside of 364.14%. Given GT Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe GT Biopharma is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryGT Biopharma beats Tenax Therapeutics on 8 of the 14 factors compared between the two stocks. Remove Ads Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.01M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-0.346.7921.7317.81Price / SalesN/A225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book0.445.866.464.00Net Income-$7.60M$141.86M$3.20B$247.23M7 Day Performance2.16%8.98%6.54%7.26%1 Month Performance-7.42%-12.65%-8.55%-6.26%1 Year Performance-36.97%-11.99%10.33%-0.18% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma3.5047 of 5 stars$2.37+3.5%$11.00+364.1%-37.0%$6.01MN/A-0.348Short Interest ↓Gap DownTENXTenax Therapeutics2.0583 of 5 stars$5.75-0.9%$18.00+213.0%+54.0%$22.83MN/A-1.089Analyst ForecastPASGPassage Bio2.3759 of 5 stars$0.35+3.0%$7.50+2,042.2%-70.0%$21.76MN/A-0.30130CARACara Therapeutics3.8999 of 5 stars$4.75-1.0%$27.84+486.1%-37.6%$21.73M$7.14M-0.2380Analyst ForecastStock SplitNews CoverageGap DownLIANLianBioN/A$0.20+0.1%N/A-33.4%$21.61MN/A-0.25110CGTXCognition Therapeutics3.1864 of 5 stars$0.35-2.0%$7.13+1,953.3%-79.9%$21.51MN/A-0.3620Gap DownFNCHFinch Therapeutics GroupN/A$13.16-2.5%N/A+492.4%$21.14M$110,000.00-1.49190OVIDOvid Therapeutics4.4257 of 5 stars$0.29+2.2%$3.03+953.6%-91.1%$20.46M$566,000.00-0.6160Gap DownLGVNLongeveron2.9999 of 5 stars$1.35-3.6%$8.67+542.0%-50.2%$20.15M$2.39M-0.2120Positive NewsPULMPulmatrix0.6161 of 5 stars$5.52+2.2%N/A+158.4%$20.15M$7.81M-2.0920Gap DownRVPHReviva Pharmaceuticals2.9951 of 5 stars$0.60+13.2%$10.00+1,566.7%-78.3%$20.07MN/A-0.545Upcoming EarningsPositive News Remove Ads Related Companies and Tools Related Companies Tenax Therapeutics Alternatives Passage Bio Alternatives Cara Therapeutics Alternatives LianBio Alternatives Cognition Therapeutics Alternatives Finch Therapeutics Group Alternatives Ovid Therapeutics Alternatives Longeveron Alternatives Pulmatrix Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GTBP Stock Free GTBP Stock Alerts